Nasdaq Stockholm

Newbury Pharmaceuticals AB

ISIN SE0015244884Filings at the FI

At a glance

Most recent filing on November 18, 2025 — an open-market purchase by Alsakali Equity AB on Nov 18, 2025.

We hold 38 visible filings, going back to January 11, 2022.

Filings we could not classify with confidence are set aside for review, so they are in none of these counts.

Insider trades

What is a MAR filing?

5 of 38 shown

This page is free to read, and it stops after 5 rows. Those are the 5 most recent filings at this company, out of 38. Reading the whole list, and the full version of the page each row opens (that page itself opens free, with its first rows), is part of the subscription. So are the price history with every buy marked, the price change beside each line, and any moments with several buyers or buying streaks. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

Alsakali Equity AB Chief executive officer
41,116 SEKOpen-market buy
TradedNov 18, 2025FiledNov 18, 2025
Alsakali Equity AB Chief executive officer
94,318 SEKOpen-market buy
TradedNov 17, 2025FiledNov 17, 2025
Alsakali Equity AB Chief executive officer
38,172 SEKOpen-market buy
TradedNov 12, 2025FiledNov 12, 2025
Johan Strömqvist Board member
305 SEKOpen-market sale
TradedApr 29, 2025FiledApr 29, 2025
Johan Strömqvist Board member
15,200 SEKOpen-market buy
TradedApr 29, 2025FiledApr 29, 2025